Taking on a more strategic role through medical
Functioning alongside R&D and commercial, medical is one of the three strategic pillars necessary for biopharmaceutical product and portfolio strategies. The medical team provides a deep understanding of the disease pathways and opportunities to intercept the disease. It is the single function that can truly place the patient at the center of a clinical and commercial strategy and provide a bridge between the two. If a differentiated, integrated and goal-oriented evidence-generation plan is to be designed and maintained, then setting a clear medical strategic direction for an asset must occur upstream. Providing medical and scientific context to the overall design and management of the portfolio is also critical and requires the medical team to play a lead role.